Laurion Capital Management LP Biomea Fusion, Inc. Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $10.9 Million - $40.3 Million	-2,632,582 Reduced 96.75%	88,401 $397,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $214,145 - $299,988	-15,384 Reduced 0.56%	2,720,983 $40.7 Million
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $4.12 Million - $9.76 Million	492,680 Added 21.96%	2,736,367 $39.7 Million
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $36.6 Million - $70.6 Million	1,689,287 Added 304.71%	2,243,687 $49.2 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $850,000 - $4.04 Million	125,000 Added 29.11%	554,400 $17.2 Million
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $87,977 - $125,906	9,251 Added 2.2%	429,400 $4.2 Million
Q2 2022 Aug 15, 2022	BUY	$3.0 - $12.03 $1.26 Million - $5.05 Million	420,149 New	420,149 $5.03 Million

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $189M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.